Skip to main content
GLMD logo

Galmed Pharmaceuticals Ltd.

GLMDNASDAQHealthcareBiotechnology

$3.62Today:- (-)1Y +164.23%

As of Oct 8, 2026 close

Market cap
$3.45M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.41$6.35
Volume (live)
-
Avg. volume (3M)
26.46K

Galmed Pharmaceuticals (GLMD) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Galmed Pharmaceuticals used $6.32M of cash in operating activities. Free cash flow was −$6.32M.

Galmed Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Galmed Pharmaceuticals Ltd. (GLMD) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Mar 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-10.31-7.52-6.91-17.87-32.47-32.47-28.77-20.46-9.86-12.30
Depreciation & Amortization0.000.080.030.040.040.040.040.040.390.24
Deferred Income Tax0.000.000.000.000.08--0.44-0.110.010.16
Stock Based Compensation0.550.530.891.301.891.892.072.231.781.39
Change in Working Capital0.91-0.730.13-2.45-2.45-2.451.103.44-1.21-1.40
Change in Accounts Receivable0.24-0.190.350.30-0.31-0.310.02-0.61-0.060.13
Change in Inventory0.000.000.00-0.300.31--0.020.61-0.140.67
Change in Accounts Payable0.70-0.57-0.21-2.31-2.18-2.181.054.19-0.46-0.85
Change in Other Working Capital-0.020.04-0.05-0.14-0.280.040.05-0.75-0.54-1.35
Other Operating Activities2.541.75-0.050.490.010.10-0.29-0.06-0.14-0.17
Net Cash from Operating Activities-6.32-5.88-6.14-18.50-32.89-32.89-26.29-14.94-9.02-12.07
Investing Activities
Capital Expenditures0.000.000.000.00-0.01-0.01-0.04-0.01-0.09-0.02
Acquisitions0.000.00-1.50-0.020.00--24.9421.806.080.00
Purchases of Investments-4.99-6.37-6.33-3.87-13.57-13.57-55.03-94.41-98.35-3.87
Sales/Maturities of Investments1.615.508.6321.4425.0421.2471.61101.1038.4210.33
Other Investing Activities0.00-0.250.000.020.003.8024.94-21.80-6.080.01
Net Cash from Investing Activities-3.38-1.110.8017.5611.4611.4616.546.68-60.026.44
Financing Activities
Common Stock Issued9.038.796.190.0717.3717.370.710.1479.1515.02
Other Financing Activities0.000.000.000.000.00-0.060.141.030.53
Net Cash from Financing Activities9.038.796.190.0717.3717.370.770.1480.1815.55
Summary
Net Change in Cash-0.661.800.85-0.87-4.06-4.06-8.98-8.1211.149.92
Cash at Beginning of Period4.772.982.133.007.067.0616.0424.1613.023.10
Cash at End of Period4.114.772.982.133.003.007.0616.0424.1613.02
Free Cash Flow-6.32-5.88-6.14-18.51-32.90-32.90-26.33-14.95-9.11-12.09

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Galmed Pharmaceuticals Cash Flow

What is Galmed Pharmaceuticals's free cash flow?

Galmed Pharmaceuticals had negative free cash flow of $6.32M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Galmed Pharmaceuticals pay dividends or buy back shares?

Galmed Pharmaceuticals's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition